Strategic partnerships Cytel has recently expanded through notable partnerships with Adial Pharmaceuticals to optimize adaptive trial design and regulatory alignment, and with Nested Knowledge to leverage AI-powered literature review. This indicates a strong and growing ecosystem approach, presenting opportunities to cross-sell HEOR and RWE services to partner networks and leverage joint offerings in adaptive design, data analytics, and evidence generation.

East Horizon expansion The launch of East Horizon in 2024 marks Cytel's advancement in clinical trial design and simulation. This platform can be positioned to potential clients seeking cutting-edge trial innovations, enabling conversations around efficiency, adaptive methods, and enhanced decision-making in late-stage development.

RWE and HEOR leadership With a three-decade leadership in analytics for biotech and pharma and strengthened by post-2020 collaborations, Cytel is well positioned to offer comprehensive HEOR and RWE services. This presents cross-sell opportunities to portfolio companies focusing on real-world evidence, health economics, and outcomes research to support market access and payer discussions.

Targeted industry growth Cytel’s recent activity around adaptive trial design, machine learning tooling, and evidence generation aligns with market trends toward more efficient trials and data-driven decision-making. This creates openings to engage mid-to-large biotechs and CROs seeking modernization, cost reduction, and accelerated timelines.

Integrated data ecosystem With a tech stack spanning Google Cloud Platform, Selenium, ggplot2, and AI tools like ChatGPT, Cytel demonstrates an ability to integrate diverse data sources and automate analytics. This can be pitched to potential clients as a foundation for scalable analytics, real-world data integration, and seamless collaboration across trial design, HEOR, and RWE projects.